Key highlights

  • Oneview Healthcare PLC (ASX:ONE) touched a 52-week low during the 20 October 2026 session and closed at $0.12, down 7.69%.
  • Oneview’s half-year report showed Recurring Revenue up 13% to €4.3 million and total revenue down 14% to €5.5 million.
  • The loss attributable to members narrowed to €5.5 million from €7.9 million, and the report refers to a Going Concern assessment.

Oneview Healthcare PLC (ASX:ONE) touched a 52-week low during the Trading session on 20 October 2026 and closed at $0.12, down 7.69%. Oneview’s latest document covered here is its Appendix 4D half-year report for the six months ended 30 June 2026. No latest announcement has driven the share price move, so the announcement is described below on its own terms.

About Oneview Healthcare

Oneview Healthcare PLC develops and sells software for the healthcare sector. Its Oneview system was live on 15,092 endpoints at 30 June 2026, compared with 14,880 previously, and it reports in euros. The company is listed on the ASX under ARBN 610 611 768.

Half-year financial results

For the six months ended 30 June 2026, recurring revenue rose 13% to €4.31 million, while non-recurring revenue fell 54% to €1.17 million, mainly due to lower project and hardware revenue. Total revenue fell 14% to €5.48 million. The loss after tax attributable to members was €5.49 million, compared with €7.89 million, an improvement of 30%.

Net tangible assets per security were €0.007, down from €0.009, with 839,193,060 securities on issue at 30 June 2026. No dividends were declared or paid.

Products and commercial activity

In May 2026 Oneview announced Bedside Hub, a new revenue channel that delivers Epic MyChart Bedside TV on healthcare-grade hardware with cloud-based device management, following certification by Epic. The company said it has engaged with a growing number of health systems evaluating Epic TV deployments. Oneview was also added to a National Care Communication Agreement with Baxter, enabling a health system to buy its products through an established commercial arrangement.

The average recurring revenue on endpoints deployed in the period was 59% higher than on the endpoints decommissioned.

Going concern and funding

The report says that since inception the group has incurred net losses and negative cash flows. In assessing the going concern basis, the directors considered current cash resources and the expected Shareholder approval and receipt of Tranche 2 proceeds from a Capital raising. The half-year financial statements form part of the interim report and are prepared on that basis.

Sector backdrop

Hospital technology suppliers sell into long procurement cycles, and moving from hardware and project revenue to recurring subscription revenue changes the shape of reported results. Integration with major electronic health record platforms can create new channels but depends on health system decisions.

Small listed healthcare technology companies often rely on capital raisings to fund losses while recurring revenue scales.

Risks shareholders should weigh

The company continues to make losses and has negative cash flows, and its going concern assessment depends on receiving Tranche 2 proceeds, which require shareholder approval. Total revenue fell 14% because non-recurring revenue fell by more than recurring revenue grew.

A larger share count after capital raisings dilutes existing holders, and net tangible assets per security fell 23%.

What’s next

Items to watch include shareholder approval and receipt of Tranche 2 proceeds, endpoint deployments and recurring revenue growth, the pipeline from the Epic MyChart Bedside TV channel and the company’s next financial report.